CN104507967B - 抗cxcr3抗体 - Google Patents

抗cxcr3抗体 Download PDF

Info

Publication number
CN104507967B
CN104507967B CN201380015401.8A CN201380015401A CN104507967B CN 104507967 B CN104507967 B CN 104507967B CN 201380015401 A CN201380015401 A CN 201380015401A CN 104507967 B CN104507967 B CN 104507967B
Authority
CN
China
Prior art keywords
antibody
antigen
seq
cxcr3
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380015401.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104507967A (zh
Inventor
M·尤德
J·特德斯通
T·洛迪
K·B·卡特
T·D·康纳斯
J·R·平克尼
E·马斯特约翰
R·丘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CN104507967A publication Critical patent/CN104507967A/zh
Application granted granted Critical
Publication of CN104507967B publication Critical patent/CN104507967B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380015401.8A 2012-01-20 2013-01-18 抗cxcr3抗体 Expired - Fee Related CN104507967B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261588936P 2012-01-20 2012-01-20
US61/588,936 2012-01-20
PCT/US2013/022280 WO2013109974A2 (en) 2012-01-20 2013-01-18 Anti-cxcr3 antibodies

Publications (2)

Publication Number Publication Date
CN104507967A CN104507967A (zh) 2015-04-08
CN104507967B true CN104507967B (zh) 2018-10-12

Family

ID=47633576

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380015401.8A Expired - Fee Related CN104507967B (zh) 2012-01-20 2013-01-18 抗cxcr3抗体

Country Status (26)

Country Link
US (4) US8865870B2 (OSRAM)
EP (1) EP2804878B1 (OSRAM)
JP (3) JP6352812B6 (OSRAM)
KR (2) KR102073034B1 (OSRAM)
CN (1) CN104507967B (OSRAM)
AR (1) AR090056A1 (OSRAM)
AU (1) AU2013209492B2 (OSRAM)
BR (1) BR112014017814A8 (OSRAM)
CA (1) CA2862222A1 (OSRAM)
CY (1) CY1121335T1 (OSRAM)
DK (1) DK2804878T3 (OSRAM)
ES (1) ES2698606T3 (OSRAM)
HR (1) HRP20181874T1 (OSRAM)
HU (1) HUE041900T2 (OSRAM)
IL (2) IL233694A0 (OSRAM)
LT (1) LT2804878T (OSRAM)
MX (1) MX359854B (OSRAM)
PL (1) PL2804878T3 (OSRAM)
PT (1) PT2804878T (OSRAM)
RS (1) RS58141B1 (OSRAM)
RU (1) RU2663141C2 (OSRAM)
SG (2) SG10201700735PA (OSRAM)
SI (1) SI2804878T1 (OSRAM)
TW (1) TWI596112B (OSRAM)
UY (1) UY34582A (OSRAM)
WO (1) WO2013109974A2 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2016028523A2 (en) 2014-08-22 2016-02-25 Sorrento Therapeutics, Inc. Antigen binding proteins that bind cxcr3
KR20180084817A (ko) 2015-10-29 2018-07-25 알렉터 엘엘씨 항-siglec-9 항체 및 이의 이용 방법
WO2017205377A2 (en) * 2016-05-23 2017-11-30 New York University Compositions and methods for antibodies targeting staphylococcal leukotoxins
TW201840585A (zh) 2016-12-22 2018-11-16 法商賽諾菲公司 用於白斑病的治療的抗人cxcr3抗體
CN110300763A (zh) * 2016-12-22 2019-10-01 赛诺菲 用于治疗白癜风的抗人cxcr3抗体
EP3559033A1 (en) 2016-12-22 2019-10-30 Sanofi Humanized cxcr3 antibodies with depleting activity and methods of use thereof
EP3752134B1 (en) 2018-02-16 2024-12-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating vitiligo
KR102074798B1 (ko) * 2018-06-15 2020-02-07 코아스템(주) 자가면역질환 치료에 대한 유효성 예측용 바이오마커, 진단키트 및 치료용 용도
JP2022507295A (ja) * 2018-11-14 2022-01-18 アーチ オンコロジー，インコーポレイテッド 治療用ＳＩＲＰα抗体
US11168128B2 (en) 2020-02-26 2021-11-09 Vir Biotechnology, Inc. Antibodies against SARS-CoV-2 and methods of using the same
WO2021222746A2 (en) * 2020-04-30 2021-11-04 Arch Oncology, Inc. THERAPEUTIC SIRPα ANTIBODIES
WO2022169825A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
CA3210655A1 (en) * 2021-03-02 2022-09-09 Novarock Biotherapeutics, Ltd. Antibodies against claudin-6 and uses thereof
KR20240043784A (ko) * 2021-08-09 2024-04-03 메르크 파텐트 게엠베하 염증유발성 시토카인의 방출로부터 t 세포-매개 종양 세포독성을 디커플링시키는 단백질
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
CN120112292A (zh) 2022-09-09 2025-06-06 爱杜西亚药品有限公司 包含抗-cd3抗体及cxcr3拮抗剂的药物组合

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184358B1 (en) * 1996-09-10 2001-02-06 Millennium Pharmaceuticals, Inc. IP-10/Mig receptor designated CXCR3, antibodies, nucleic acids, and methods of use therefor
WO2001072334A2 (en) * 2000-03-27 2001-10-04 Corixa Corporation Methods for treating disease with antibodies to cxcr3
WO2005030793A2 (en) * 2003-09-24 2005-04-07 Millennium Pharmaceuticals, Inc. Antibodies which bind human cxcr3
CN101796073A (zh) * 2007-02-01 2010-08-04 联合基因系统公司 针对cxcr3的人源化抗体

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565332A (en) 1896-08-04 Toy for making soap-bubbles
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3546806C2 (OSRAM) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
JP2826272B2 (ja) 1993-10-26 1998-11-18 タイガースポリマー株式会社 中空樹脂成形品の製造装置及び製造方法
US5565352A (en) 1993-11-24 1996-10-15 Arch Development Corporation Deubiquitinating enzyme: compositions and methods
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
ES2288305T3 (es) * 1996-09-10 2008-01-01 Theodor-Kocher Institute Receptor de quimiocinas cxcr3, anticuerpos, acidos nucleicos y metodos de uso.
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
CA2536644A1 (en) * 2003-06-30 2005-02-03 Bio-Technology General (Israel) Ltd. Antibodies and uses thereof
JP4695133B2 (ja) * 2004-03-23 2011-06-08 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
BRPI0514259A (pt) 2004-08-11 2008-06-03 Trubion Pharmaceuticals Inc proteìna de fusão de domìnio de ligação
BRPI0710011A2 (pt) 2006-04-14 2011-08-02 Trubion Pharmaceuticals Inc proteìnas de ligação compreendendo articulação de imunoglobulina e regiões fc dotadas de funções efetoras fc alteradas
MY159201A (en) 2007-08-29 2016-12-30 Sanofi Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2010056907A2 (en) 2008-11-12 2010-05-20 The Scripps Research Institute Compounds that induce pancreatic beta-cell expansion
WO2010103517A1 (en) 2009-03-12 2010-09-16 Rappaport Family Institute For Research In The Medical Sciences Soluble compositions for the treatment of cxcr3-ligand associated diseases
CN102869680B (zh) * 2010-02-26 2016-10-05 生命北极神经科学公司 原细纤维结合抗体及其在帕金森氏症、路易体痴呆和其他α-共核蛋白病的治疗和诊断方法中的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184358B1 (en) * 1996-09-10 2001-02-06 Millennium Pharmaceuticals, Inc. IP-10/Mig receptor designated CXCR3, antibodies, nucleic acids, and methods of use therefor
WO2001072334A2 (en) * 2000-03-27 2001-10-04 Corixa Corporation Methods for treating disease with antibodies to cxcr3
WO2005030793A2 (en) * 2003-09-24 2005-04-07 Millennium Pharmaceuticals, Inc. Antibodies which bind human cxcr3
CN101796073A (zh) * 2007-02-01 2010-08-04 联合基因系统公司 针对cxcr3的人源化抗体

Also Published As

Publication number Publication date
US20190119391A1 (en) 2019-04-25
SI2804878T1 (sl) 2018-12-31
CN104507967A (zh) 2015-04-08
TW201335188A (zh) 2013-09-01
US8865870B2 (en) 2014-10-21
MX2014008728A (es) 2015-07-06
US20130251733A1 (en) 2013-09-26
HRP20181874T1 (hr) 2019-01-11
EP2804878B1 (en) 2018-08-22
BR112014017814A2 (OSRAM) 2017-06-20
PT2804878T (pt) 2018-11-29
HK1208684A1 (en) 2016-03-11
US20180086838A1 (en) 2018-03-29
LT2804878T (lt) 2018-12-10
RU2014134043A (ru) 2016-03-20
PL2804878T3 (pl) 2019-03-29
SG11201406762QA (en) 2014-11-27
SG10201700735PA (en) 2017-02-27
RU2663141C2 (ru) 2018-08-01
WO2013109974A2 (en) 2013-07-25
AR090056A1 (es) 2014-10-15
EP2804878A2 (en) 2014-11-26
IL233694A0 (en) 2014-09-30
RS58141B1 (sr) 2019-02-28
KR20140116525A (ko) 2014-10-02
US9765144B2 (en) 2017-09-19
HUE041900T2 (hu) 2019-06-28
UY34582A (es) 2013-09-02
KR20200014441A (ko) 2020-02-10
CA2862222A1 (en) 2013-07-25
AU2013209492B2 (en) 2018-02-08
JP2018166506A (ja) 2018-11-01
CY1121335T1 (el) 2020-05-29
BR112014017814A8 (pt) 2017-07-11
TWI596112B (zh) 2017-08-21
IL271697A (en) 2020-02-27
DK2804878T3 (en) 2018-12-17
ES2698606T3 (es) 2019-02-05
WO2013109974A3 (en) 2013-11-07
US20140377806A1 (en) 2014-12-25
JP2020072715A (ja) 2020-05-14
JP2015506945A (ja) 2015-03-05
AU2013209492A1 (en) 2014-08-14
KR102073034B1 (ko) 2020-02-05
JP6352812B6 (ja) 2018-08-08
MX359854B (es) 2018-10-12
JP6646100B2 (ja) 2020-02-14
JP6352812B2 (ja) 2018-07-04

Similar Documents

Publication Publication Date Title
CN104507967B (zh) 抗cxcr3抗体
CN110407941B (zh) Cd39的高亲和力抗体及其用途
CN106029695B (zh) 拮抗性抗犬pd-1抗体
US20100136030A1 (en) Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
KR20080080639A (ko) 항-ｏｘ40ｌ 항체 및 그의 사용 방법
CN117062834A (zh) Gpc3人源化抗体及其应用
WO2014186842A1 (en) Antibodies and uses thereof
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
EP3559033A1 (en) Humanized cxcr3 antibodies with depleting activity and methods of use thereof
WO2018119288A1 (en) Anti-human cxcr3 antibodies for treatment of vitiligo
HK1208684B (zh) 抗cxcr3抗體
HK40016809B (en) High affinity antibodies to cd39 and uses thereof
HK40016809A (en) High affinity antibodies to cd39 and uses thereof
EP3559036A1 (en) Anti-human cxcr3 antibodies for treatment of vitiligo

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1208684

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20181012

Termination date: 20220118